Halle Moore, MD, discusses a phase III trial that looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.
Halle Moore, MD, medical oncologist, Cleveland Clinic, discusses aphase III trial presented at the 2014 ASCO Annual Meetingthat looked at reducing the risk of premature ovarian failure with LHRH analog administration with chemotherapy in women with breast cancer.
<<<
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen